Mobile app to help children after stem cell transplants take their medications
BMT4me: Improving Adherence Through mHealth for Pediatric Stem Cell Transplant Patients (BMT4me 2.0)
NA · Nationwide Children's Hospital · NCT05515497
This study is testing a mobile app to help kids who have had stem cell transplants remember to take their medications, making it easier for their families to keep track.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 0 Years to 21 Years |
| Sex | All |
| Sponsor | Nationwide Children's Hospital (other) |
| Locations | 1 site (Columbus, Ohio) |
| Trial ID | NCT05515497 on ClinicalTrials.gov |
What this trial studies
This pilot study evaluates the acceptability and feasibility of the BMT4me mobile health app designed to improve medication adherence among children who have undergone hematopoietic stem cell transplants. It focuses on caregivers of pediatric patients in the acute post-transplant phase, aiming to address the challenges of medication adherence through a user-friendly digital platform. The study will assess how well the app can engage families and improve adherence to immunosuppressant medications, which is critical for the health of these children.
Who should consider this trial
Good fit: Ideal candidates are children aged 0 to 21 who are receiving immunosuppression after an allogeneic transplant or anti-infective treatment for an autologous transplant.
Not a fit: Patients who are adults unable to consent or those not living with a primary caregiver who can enroll in the study may not benefit from this intervention.
Why it matters
Potential benefit: If successful, this app could significantly improve medication adherence in pediatric patients post-transplant, potentially reducing hospital readmissions and healthcare costs.
How similar studies have performed: While there are few studies on adherence in pediatric HSCT, none have specifically addressed immunosuppressant adherence through a randomized controlled trial, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children of caregivers must be a) 0 to 21 years of age; b) receiving immunosuppression for an allogeneic transplant or anti-infective for an autologous transplant; c) discharged prior to Day 100 or completion of immunosuppression taper, and d) residing with the primary caregiver that enrolls on the study. * Primary caregivers must be: d) English-speaking; and e) have an iOS or Android capable cellular device. Exclusion Criteria: * Adults unable to consent
Where this trial is running
Columbus, Ohio
- Nationwide Children's Hospital — Columbus, Ohio, United States (RECRUITING)
Study contacts
- Study coordinator: Micah A Skeens, PhD, APRN, CPNP
- Email: Micah.Skeens@nationwidechildrens.org
- Phone: (614) 722-8958
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Stem Cell Transplant, Adherence, Medication, Digital Health, Adherence, mHealth, Stem Cell transplant, Immunosuppression, Pediatrics